[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630946":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":30,"responsibleParty":46,"collaborators":50,"id":52,"slug":26,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":26,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":26,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":26,"overallStatus":71,"whyStopped":26,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Liaquat University of Medical & Health Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Nisatol®","EXPERIMENTAL","Participants randomized to this arm will receive Nigella sativa extract (Nisatol®) capsules (2 capsules per day, one capsule in the morning and one in the evening) for 12 weeks.",[13],"Dietary Supplement: Nigella sativa (Nisatol®)",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants randomized to this arm will receive placebo capsules identical in appearance to the Nisatol® capsules (2 capsules per day, one capsule in the morning and one in the evening) for 12 weeks.",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Nigella sativa (Nisatol®)","Standardized Nigella sativa extract (Nisatol®) administered orally 2 capsules per day (one capsule in the morning and one in the evening) for 12 weeks.",[9],null,{"type":6,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Placebo capsules identical in appearance to the Nigella sativa (Nisatol®) 2 capsules per day administered for 12 weeks.",[15],[31],{"facility":32,"status":26,"city":33,"state":26,"zip":26,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"University of Rome Tor Vergata","Roma","Italy",{"type":36,"coordinates":37},"Point",[38,39],11.10642,44.99364,{"lat":39,"lon":38},[42],{"name":43,"role":44,"phone":26,"phoneExt":26,"email":45},"Prof. Laura Di Renzo, PhD","CONTACT","laura.di.renzo@uniroma2.it",{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Dr. Amjad Khan","Professor",[51],{"name":32,"class":6},"100630946",false,"NCT07494279","Efficacy of Nigella Sativa (Nisatol®) in Women With Borderline Blood Pressure Values or a Non-Dipper Blood Pressure Phenotype","Efficacy of Nigella Sativa (Nisatol®) Supplementation in Women With Borderline Blood Pressure Values or a Non-Dipper Blood Pressure Phenotype: A Randomized Placebo-Controlled Study With Dietary Intervention Phase","Inclusion Criteria\n\n* Female participants\n* High-normal blood pressure values (≥130\u002F85 mmHg) or mild hypertension (140\u002F90 mmHg) with low cardiovascular risk and no current indication for pharmacological therapy\n* Presence of a non-dipper blood pressure phenotype on 24-hour ambulatory blood pressure monitoring\n* Absence of antihypertensive pharmacological treatment Exclusion Criteria\n* History of cardiovascular disease\n* Diabetes mellitus\n* Severe chronic diseases\n* Use of medications affecting blood pressure or heart rate\n* Known allergy to Nigella sativa or fennel","FEMALE","18 Years","65 Years",{"count":62,"type":63},106,"ESTIMATED","INTERVENTIONAL",[66],"NA","This randomized placebo-controlled study evaluates the efficacy of Nigella sativa (Nisatol®) supplementation in women with borderline blood pressure values or a non-dipper blood pressure phenotype. The study aims to assess the effects of supplementation on blood pressure and resting heart rate in women presenting high-normal blood pressure values (≥130\u002F85 mmHg) and\u002For a nocturnal non-dipper blood pressure pattern.\n\nParticipants will be randomly assigned to receive either Nigella sativa (Nisatol®) or placebo for 12 weeks. After the treatment phase, a washout period will be followed by a dietary intervention phase combined with alternate treatment according to the study design. Cardiological and nutritional assessments will be performed at predefined time points.",[69,70],"Prehypertension","Hypertension","NOT_YET_RECRUITING","2026-03-20",{"date":74,"type":75},"2026-03-27","ACTUAL",{"date":77,"type":63},"2026-03-30",{"date":79,"type":63},"2026-12-31",{"name":5,"class":6},1]